Immunomedics (IMMU) Set to Announce Earnings on Wednesday

Immunomedics (NASDAQ:IMMU) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, August 7th. Analysts expect Immunomedics to post earnings of ($0.31) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.10). During the same quarter in the prior year, the business posted ($0.21) EPS. On average, analysts expect Immunomedics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of IMMU traded up $0.41 during mid-day trading on Tuesday, reaching $14.02. The company had a trading volume of 26,941 shares, compared to its average volume of 1,564,858. The firm has a market capitalization of $2.61 billion, a PE ratio of -13.57 and a beta of 1.98. The company’s fifty day simple moving average is $14.25. Immunomedics has a fifty-two week low of $11.55 and a fifty-two week high of $26.99. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.89 and a current ratio of 7.89.

A number of brokerages have weighed in on IMMU. BidaskClub upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a report on Friday, June 28th. ValuEngine raised shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Cowen set a $30.00 target price on shares of Immunomedics and gave the company a “buy” rating in a research note on Wednesday, July 31st. Piper Jaffray Companies set a $20.00 target price on shares of Immunomedics and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $28.00 target price on shares of Immunomedics in a research note on Monday, May 13th. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $28.45.

In other Immunomedics news, Director Avoro Capital Advisors Llc purchased 400,000 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The stock was acquired at an average cost of $13.25 per share, with a total value of $5,300,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Bryan Ball purchased 5,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The stock was acquired at an average cost of $13.35 per share, with a total value of $66,750.00. Following the completion of the acquisition, the insider now directly owns 5,000 shares in the company, valued at approximately $66,750. The disclosure for this purchase can be found here. Insiders bought a total of 4,976,078 shares of company stock valued at $66,108,902 in the last three months. Insiders own 9.40% of the company’s stock.

Immunomedics Company Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Read More: What is the float in trading stocks?

Earnings History for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.